Elementis
OTCMKTS:ELMTYElementis plc operates as a specialty chemical company in the United Kingdom, rest of Europe, North America, and internationally. It operates through Personal Care, Coatings, and Talc segments. The Personal Care segment provides rheological modifiers and compounded products, including active ingredients for AP deodorants, for personal care manufacturers. The Coating segment produces rheological modifiers and additives for decorative and industrial coatings. The Talc segment engages in the production and supply of talc for plastics, coatings, technical ceramics, and the paper sectors. The company also offers personal care products for antiperspirants/deodorants, bath and soap, color cosmetics, and hair and skin care products; and coating products for adhesive and sealants, architectural coatings, ceramics, colorant dispersions, construction, drilling fluid additives, industrial finishes, inks, and lubricant additive application, as well as paints and coating, paper, plastics, polyester putties, pulp, stimulation, and specialty applications. It also offers talc products for food and pharmaceuticals markets. The company was founded in 1844 and is headquartered in London, the United Kingdom.
Japan Steel Works
OTCMKTS:JPSWYThe Japan Steel Works, Ltd. engages in the provision of industrial machinery products, and material and engineering business in Japan and internationally. It operates through Industrial Machinery Products Business, and Material and Engineering Business segments. The Industrial Machinery Products Business segment offers plastic production and processing machinery, such as pelletizers, film and sheet manufacturing equipment, and twin-screw extruders; molding machines including plastic injection molding, magnesium injection molding, and blow molding machines; and other machinery consists of excimer laser annealing systems, defense equipment, railway products, hot press devices, vacuum laminators, and deposit systems, as well as after-sales services for plastics, mobility, high-performance batteries, electronic devices, and defense applications. The Material and Engineering Business segment provides steel casting and forgings, such as reactor and steam generator parts, rotor shafts, turbine casings, die steel, steel rolls for steel manufacturing, and clad steel plates; and engineering and other services, including design and analysis, welded structures, inspection and survey, and hydrogen pressure accumulators and related products for use in power generation equipment, renewable energy, and infrastructure applications. The company offers photonics, composite materials, and metallic materials for use in semiconductors and electronic devices, cameras and sensing devices, aircraft and mobility components, and electronic parts. The Japan Steel Works, Ltd. was founded in 1907 and is headquartered in Shinagawa, Japan.
Morgan Advanced Materials
OTCMKTS:MCRUFMorgan Advanced Materials plc operates as a materials science and application engineering company primarily the United Kingdom. It serves customers in the industrial, transportation, petrochemical and chemical, energy, semiconductor and electronics, healthcare, and security and defense markets. The company was formerly known as The Morgan Crucible Company plc and changed its name to Morgan Advanced Materials plc in March 2013. Morgan Advanced Materials plc was founded in 1856 and is headquartered in Windsor, the United Kingdom.
Pharma Mar
OTCMKTS:PHMMFPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Salzgitter
OTCMKTS:SZGPYSalzgitter AG, together with its subsidiaries, engages in steel and technology businesses worldwide. It operates through four segments: Steel Production, Steel Processing, Trading, and Technology. The Steel Production segment manufactures steel and special steels, such as hot-rolled wide strip, steel sheet, sections, tailored blanks, as well as scrap trading. The Steel Processing segment produces various high-grade heavy plates; and manufactures line pipes, HFI-welded tubes, and precision and stainless-steel tubes. The Trading segment operates a European sales network, as well as trading companies and agencies worldwide. The Technology segment engages in the provision of machinery and plants for the filling and packaging of beverages, as well as special machinery engineering for shoe manufacturing and elastomer production. The company also provides IT, facility management, logistics, automotive engineering, and research and development services, as well as supplies raw materials. Salzgitter AG was founded in 1858 and is headquartered in Salzgitter, Germany.